• 888-778-6481

    Are oncolytic viruses the next generation cancer therapy

    Talimogene laherparepvec (T-VEC) would likely be the first among a number of virus-based cancer treatments in the pharma pipeline to be approved by FDA. T-VEC, which is injected directly into melanoma tumors, is a version of herpes simplex virus that has been genetically modified so it only replicates in cancer cells, destroying tumors while sparing healthy tissues. It also includes a gene that encodes a type of cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), which recruits immune-boosting cells to the tumor. The hope is that the combination of the virus with GM-CSF will not only speed up the drug’s cancer-killing effect, but also stimulate the immune system to continue killing melanoma cells—even those that have traveled away from the treated tumor.
    With our proprietary gene synthesis and cutting edge molecular biology technology, General Biosystem assists the research on genetic engineering of oncolytic viruses and therapeutic antibodies.